Clinical Trial Update: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is exploring RC48-ADC in combination therapies as first-line treatment for advanced/metastatic gastric cancer; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Gastric Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING